AQST Jun 2024 2.500 put
| Previous Close | 0.1000 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.0500 |
| Strike | 2.50 |
| Expire Date | 2024-06-21 |
| Day's Range | 0.0500 - 0.0500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 143 |
GlobeNewswireAquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film
Anaphylm pharmacokinetic results unaffected by oral cavity exposure to liquids of different temperatures and pHRemains on track to complete Anaphylm supportive clinical studies and expects to request pre-NDA meeting with FDA in the third quarter 2024Continues to anticipate filing a New Drug Application (NDA) shortly after completion of its pediatric study of Anaphylm WARREN, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a phar
Simply Wall St.Investors in Aquestive Therapeutics (NASDAQ:AQST) have unfortunately lost 36% over the last five years
Ideally, your overall portfolio should beat the market average. But the main game is to find enough winners to more...
- GlobeNewswire
Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024
WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced its expected addition to the broad-market Russell 3000® and Russell 2000® Indexes at the conclusion of the 2024 Russell U.S. indexes annual reconstitution, effective at the open of U.S. equity markets on Monday
